Aim/hypothesis. Embryonic stem (ES) cells have been proposed as a potential source of tissue for transplantation for the treatment of Type 1 diabetes. However, studies showing differentiation of beta cells from ES cells are controversial. The aim of this study was to characterise the insulin-expressing cells differentiated in vitro from ES cells and to assess their suitability for the treatment of diabetes. Methods. ES cell-derived insulin-expressing cells were characterised by means of immunocytochemistry, RT-PCR and functional analyses. Activation of the Insulin I promoter during ES-cell differentiation was assessed in ES-cell lines transfected with a reporter gene. ES cell-derived cultures were transplanted into STZ-treated SCID-beige mice and blood glucose concentrations of diabetic mice were monitored for 3 weeks. Results. Insulin-stained cells differentiated from ES cells were devoid of typical beta-cell granules, rarely showed immunoreactivity for C-peptide and were mostly apoptotic. The main producers of proinsulin/insulin in these cultures were neurons and neuronal precursors and a reporter gene under the control of the insulin I promoter was activated in cells with a neuronal phenotype. Insulin was released into the incubation medium but the secretion was not glucose-dependent. When the cultures were transplanted in diabetic mice they formed teratomas and did not reverse the hyperglycaemic state. Conclusions/Interpretation. Our studies show that insulin-positive cells in vitro-differentiated from ES cells are not beta cells and suggest that alternative protocols, based on enrichment of ES cell-derived cultures with cells of the endodermal lineage, should be developed to generate true beta cells for the treatment of diabetes. [Diabetologia (2004) 47:499-508] 
Introduction
Diabetes mellitus affects millions of people worldwide. Whereas Type 2 diabetes is due to the development of insulin-resistance in peripheral tissues and progressive failure of beta cells to produce insulin, Type 1 diabetes results from autoimmunitary destruction of the beta cells. A significant advance in the search for the cure of Type 1 diabetes has been recently accomplished with the development of an islet transplant-protocol that successfully achieves insulin independence in Type 1 diabetic patients [1] . Unfortunately, the scarce availability of donor tissue limits the applicability of this therapy. To overcome this problem researchers have focused on the development of possible alternative sources of transplantable tissue.
Embryonic stem (ES) cells have been proposed as a potential source of islet tissue since they can differentiate in vitro into several different cell types [2, 3, 4, 5, 6, 7] . Enthusiasm was raised in the scientific community with a report that ES cells could differentiate into pancreatic islet-like structures [8] . The authors of that study had noticed that, although originating from a different germ layer, the development of the pancreas shared similarities with the development of the nervous system [9, 10, 11] . Therefore, they adapted a strategy used to generate neurons [6] to derive endocrine pancreatic cells from ES cells. This protocol involved sequential in vitro differentiation steps during which cultures were highly enriched in cells expressing nestin, an intermediate filament present in neural stem cells [12] , but also expressed in a small population of pancreatic cells that have been proposed as possible islet precursors [13, 14] . The nestin-positive cells were further differentiated into structures morphologically resembling pancreatic islets, connected to each other by a web of neurons, with insulinexpressing cells localised inside these structures and glucagon-positive cells at the periphery. The only caveat of this system seemed to be the low cellular insulin content of the beta cells and the failure of the islet-like structures to correct hyperglycaemia in diabetic mice.
Two other studies have been recently published with suggestions on conditions that would improve the original protocol, leading to the production of insulin-positive cells able to rescue streptozotocyn-treated animals [15, 16] . More recently, however, it has been shown that insulin immunoreactivity in ES cell cultures may be due to insulin uptake from the medium, rather than insulin production [17] . In this study, contrary to previous reports, no message for insulin was detectable in culture. Therefore, it is now a matter of controversy whether true pancreatic beta cells can be differentiated from ES cells with the protocols so far developed.
We reproduced the original protocol for the differentiation of islet-like structures and further characterised the system and its potential suitability for the reversion of a diabetic condition. Our results support and complement previous observations [17] and clarify the controversy of differentiation of ES cells into pancreatic islets.
Materials and methods
Cell culture and in vitro differentiation of ES cells. Three mouse ES cell lines, AB1, D388 and J1, maintained on irradiated embryonic fibroblasts were used in the experiments. Differentiation into insulin-positive cells was done according to [8] with slight modification. Briefly, ES cells were grown in the absence of feeder layer on gelatin-coated dishes for two passages (Stage 1). Embryoid bodies were grown in suspension for 4 days in the absence of LIF (Stage 2), then transferred to gelatin-coated tissue culture dishes and incubated for 7 to 8 days in serum-free ITSF medium [6] (Stage 3). Cultures were then trypsinized and passed onto poly-ornithine/laminin coated dishes or coverslips, and grown in N2 medium supplemented with B27 (GIBCO, Grand Island, N.Y., USA), 20 µg/ml insulin, 1 µg/ml laminin (Sigma Chemical, St. Louis, Mo., USA), 10 µg/ml bFGF and 10 µg/ml EGF (R&D Systems, Minneapolis, Minn., USA) (Stage 4). After 7 days bFGF and EGF were withdrawn and 10 mmol/l nicotinamide (Sigma Chemical) was added to the medium for the next 7 days (Stage 5).
Generation of ES cell lines stably expressing EGFP driven by
the Insulin promoter. J1 cells were transfected with the plasmid −410rINS1-d2EGFP (a kind gift from Dr. T. Kieffer, UBC) [18] . The transgenic promoter comprised 410 bp upstream of the transcriptional initiation site of the Insulin I gene and thus included all of the positive regulatory cis-acting elements of murine insulin I promoter [19] . Cell transfection was done using Lipofectamine (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's instructions. pcDNA3.1 vector (Invitrogen) was co-transfected for neomycin selection of recombinant clones. Resistant clones were screened for genome integration of the rat Insulin I promoter and d2EGFP cDNA by genomic PCR. Positive clones were isolated and differentiated using the protocol described above. Two different clones (J1/I5 and J1/I11), in which EGFP expression was activated as a result of the differentiation procedure, were used in the experiments.
Immunocytochemistry. Cells grown on coverslips were fixed in 4% paraformaldehyde in PBS for 45 min at 4°C. Non-specific binding-sites were blocked with 4% goat serum in PBS for 1 h at room temperature. Incubations with the primary and secondary antibodies were done for 1 h at room temperature. The following primary antibodies were used: guinea pig anti-insulin (1:1000, Dako, Carpinteria, Calif., USA), mouse anti-glucagon (1:7500, Sigma), mouse anti-nestin (1:200, BD Pharmingen, San Diego, Calif., USA), mouse anti-ß3 tubulin (1:150, Chemicon, Temecula, Calif., USA), mouse anti-GAP-43 (1:500, Sigma), rabbit anti-synaptophysin (1:100, Dako) and rabbit anti-C-Peptide (1:100, Linco, St. Charles, Mo., USA). Secondary antibodies were: anti-guinea pig Alexa 488 and Alexa 594, goat anti-rabbit Alexa 488, goat anti-rabbit Alexa 546 (1:1000, Molecular Probes, Eugene, Ore., USA), and goat anti-mouse Texas Red (1:200, Caltag Laboratories, Burlingame, Calif., USA). TUNEL reaction (Boehringher Mannheim, Mannheim, Germany) was done according to the manufacturer's instructions.
RT-PCR.
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Mississauga, Ont., Canada). RNA samples were digested with DNaseI (Invitrogen) and retrotranscribed with SuperScript II (Invitrogen) following the manufacturer's instructions.
PCR was done with HiFi Taq polymerase (Invitrogen) according to the manufacturer's instructions for 30 cycles (40 cycles for pancreatic polypeptide).
Insulin secretory activity and hormone content. Stage 5 cultures were pre-incubated overnight in regular or in insulin-free medium. Duplicate aliquots of cells were incubated in medium containing 2.8 mmol/l or 20 mmol/l glucose for 2 h at 37°C. Insulin secretion into the incubation medium was assessed with an insulin radioimmunoassay (RIA) kit (Linco). Cellular insulin content was assessed after extraction in 2 mmol/l acetic acid containing 0.25% BSA. A p value of less than 0.05 was considered statistically significant.
Transplantation in diabetic mice. Stage 5 cultures were transplanted under the left kidney capsule of streptozotocin (250 mg/kg) induced-diabetic SCID-beige mice (Jackson Laboratories/Harbor, Me., USA). Twelve mice (all 6-8 week-old males) were implanted in two independent experiments. Aliquots consisting of approximately 4 million cells were aspirated into polyethylene tubing, pelleted by centrifugation, and gently placed under the kidney capsule with the aid of a micromanipulator syringe. Mice were subsequently monitored twice a week for blood glucose values. All animal experimental procedures were carried out according to the guidelines of the Canadian Council on Animal Care.
Results

Clusters of insulin-positive cells derived from ES cells.
To differentiate ES cells into insulin-expressing cells we used a multi-step protocol described previously [8] . (Fig. 1D) . No insulin granules-a distinctive feature of beta cells, were observed with electron microscopy.
Proinsulin is synthesized in nestin-positive precursors and neurons. Although the cells that stained for insulin did not usually stain for neuronal markers such as βIII-tubulin or synaptophysin, a distinct punctated insulin staining was observed in some neuronal axons (Fig. 1E-G) and in the cytoplasm of synaptophysinexpressing cells (Fig. 1H-J) .
To specifically address the presence of endogenously produced insulin in our cultures we used an antibody against C-peptide. This antibody recognises the mature C-peptide and proinsulin, but not insulin. Since only the mature form of insulin is added to the medium, immunoreactivity for C-peptide/proinsulin would indicate that the precursor proinsulin is synthetised by cells in culture. Immunoreactivity for C-peptide was indeed present in our cultures. Unexpectedly, in most cases the anti-C-peptide/proinsulin and the anti-insulin antibodies (the latter one not recognising the precursor proinsulin) stained different populations of cells ( Fig. 2A,C) , the C-peptide/proinsulin staining being localised in nestin-positive (Fig. 2B ) and neuron-like cells and along axonal processes (Fig. 2B,D) . Only a minor fraction of cells showed co-expression of C-peptide/proinsulin and mature insulin, and even in these cases the mature hormone was often present in a different subcellular compartment than the C-peptide/proinsulin ( Fig. 2E-I ). We did not observe staining for glucagon in our cultures, although we saw expression of glucagon mRNA by RT-PCR in isolated experiments.
ES-derived cultures express insulin mRNA and transcription factors associated with pancreatic and neuronal development.
RT-PCR analysis was done on cultures at different stages during the differentiation procedure. We found that transcription factors that are known to be involved in pancreas and nervous system development were expressed at early stages of differentiation (Fig. 3) . No PP mRNA was detectable at any stage.
In rodents there are two non-allelic insulin genes, Insulin I and II, both expressed and regulated in beta cells [19] . In our cultures the Insulin II mRNA was always detectable. We rarely observed Glucagon and Insulin I mRNA; however, in most of the cultures the mRNAs for these genes were undetectable.
Transgenic Insulin I gene promoter is activated early in cells resembling neurons.
To facilitate identification and analysis of the insulin-positive cells that differentiate from ES cells, we generated stable ES-cell clones expressing the enhanced green fluorescent protein (d2EGFP) under control of the rat Insulin I promoter.
Upon differentiation, the transgenic clones formed clusters of cells exactly as described above for the parental non-transfected ES cells. (Fig. 4A) . When we stained the cultures with antibodies against the neural-specific Growth-Associated Protein-43 (GAP-43), we found that, although GAP-43 and EGFP were expressed in two largely distinct cell populations, few cells co-expressed both (Fig. 4B) .
Immunocytochemistry of the cultures at Stage 4 and Stage 5 showed that no insulin-positive cells expressed EGFP and no EGFP-expressing cells stained for mature insulin (Fig. 4C) . However, when we used the antibody against the C-peptide/proinsulin we occasionally observed cells with double labelling (Fig. 4D) .
RT-PCR analysis performed on FACS-sorted EGFP-positive cells showed that the endogenous Insulin I gene was not expressed in these cells, despite the activation of the transgenic insulin I promoter, neither was Pdx1. Insulin secretory activity is not glucose-dependent. An essential feature of pancreatic beta cells is the ability to release insulin in response to high glucose concentration. Although the ES cell-derived cultures did secrete insulin into the medium, the cells did not exhibit an increased secretory activity in response to glucose (Fig. 5A) . Identical results were obtained when the assay was done with sorted EGFP + and EGFP − cells. Since it has been proposed that insulin can be taken up from the medium and then released by dying cells ▲ [17] , we pre-incubated the cultures for 18 h in medium with (25 µmol/l insulin, i.e. the concentration routinely added to the differentiation medium) or without insulin, before the insulin-release assay. Cultures preincubated in insulin-free medium not only secreted less insulin (p<0.05, Fig. 5A ), but also their intracellular insulin content was reduced (Fig. 5B) . For comparison with normal islets, a mouse beta cell contains an average of 30 pg of insulin, 6 to 8% of which is released over 2 h of incubation in high-glucose medium (accounting for an average release of 2 µg of insulin/10 6 cells). In the absence of insulin in the pre-incubation medium, the ES cell-derived cultures contained 1000-fold less insulin than a mouse beta cell and since the insulin secreted over 2 h was approximately the same of the intracellular content, our data suggest that insulin was secreted through a constitutive pathway.
Transplantation does not correct diabetes in SCID mice.
After streptozotocin administration, all mice had blood glucose concentrations above 20 mmol/l. However, all animals implanted with stage 5 derived cells did not show any reduction in blood glucose. Due to the prolonged hyperglycaemia and poor health of the animals, mice were killed between 15 to 25 days posttransplant. When the grafts were examined histologically, no insulin or Pdx1 positive cells were observed and the morphology of the graft resembled a teratoma.
Discussion
Recently several studies have reported the ability to differentiate insulin-positive cells and pancreatic isletlike structures from ES cells [8, 15, 16] . The production of insulin-expressing cells in these studies, however, has been questioned since using the same differentiation protocol, it was shown that insulin immunoreactivity was due to insulin uptake from the medium rather than endogenous synthesis of the hormone [17] . It is not yet clear whether this phenomenon could have been responsible for all the insulin immunoreactivity observed in the previous studies. Whereas in that study no insulin mRNA was detectable [17] , in the other studies insulin expression was present [8, 15, 16] . Therefore, in the absence of conclusive data regarding the nature of the cells that do express insulin message in culture, it is still controversial whether beta cells can be generated with Lumelsky's protocol.
In our experiments, the potential of ES cells to generate cells of the endoderm lineage and, consequently, pancreatic precursors was probably lost when the cultures were selectively enriched with cells expressing nestin [8] . This step had its original motivation in reports indicating pancreatic nestin-positive cells as potential precursors of islets [13, 14] . In our cultures, up to 80% of the cells were nestin-positive after selective enrichment. Insulin-positive cells differentiated into Insulin expressing cells from differentiated embryonic stem cells are not beta cells 505 clusters of nestin cells. However, recent studies have strongly argued against a role of nestin-expressing cells in the development of the pancreas and, consequently, against the possibility that true beta cells might be derived in vitro from nestin-expressing precursors [21, 22, 23, 24, 25, 26] . In the ES cell-derived cultures we observed expression of transcription factors involved in the development of the pancreas [8, 27, 28] . We also detected expression of Pdx1, a key player in pancreas ontogenesis [29] and mature beta-cell physiology [30] , expression of which had been elusive in previous studies. Similar data had suggested in the past, that a program of pancreatic differentiation had been activated in culture [8] . However, the same transcription factors appear to be involved in the development of the nervous system [31, 32] . Pdx1 has been shown to be expressed in neural precursors in different embryonic brain regions [33] and Ngn3, transiently expressed in the spinal cord and hypothalamus, seems to be involved in the development of specific types of interneurons and in the process of glia differentiation [34, 35] . Since our cultures were highly enriched in neurons and neuronal precursors, we believe that expression of those transcription factors occurred in cells of the neural lineage. This hypothesis is supported by the fact that, while in islet progenitors the transcription factor Ngn3 as well as pancreatic polypeptide are transiently expressed [36, 37] , in our cultures only Ngn3 was expressed.
In contrast to a previous report [17] we did observe expression of insulin mRNA in the cultures, along with synthesis of the insulin precursor. Indeed, a considerable number of cells showed immunoreactivity when stained with an antibody against C-peptide/proinsulin. Unexpectedly, however, the majority of the immunoreactivity was localised in neurons and nestinpositive cells. Insulin expression in neuronal cultures and in the nervous system has been reported (reviewed in [38] ), leading to the hypothesis that insulin could have a role during the development of the nervous system [39, 40, 41, 42] .
In pancreatic beta cells C-peptide and mature insulin are present in equimolar ratios and co-localise in the secretory granules [20, 43] . In our cultures the C-peptide/proinsulin immunoreactivity was largely distinct from that of insulin, with co-expression limited to a small subset of the insulin-positive cells. Even in the case in which both C-peptide/proinsulin and insulin immunoreactivity were present in the same cells, the subcellular distribution was only partially overlapping. Since the anti-C-peptide antibody used in this study cross-reacts with both mature C-peptide and proinsulin (but not with mature insulin), we could not assess which molecular species was responsible for the observed immunostaining. However, since the majority of C-peptide-positive cells did not stain for mature insulin we speculate that the immunoreactivity was due to unprocessed proinsulin. Our hypothesis is supported by studies showing that in the developing nervous system (or at least in specific areas of it), the majority of proinsulin is not processed to the mature form [44, 45, 46] .
On the other hand, the majority of insulin-positive cells that were not reactive to the C-peptide/proinsulin antibody may have taken up insulin from the medium [17] . In addition, the majority of the insulin-positive cells showed signs of necrosis and/or apoptosis and, it is tempting to speculate that they could represent dying cells (nestin precursors, neurons or other cell types). Furthermore, stimulation with high glucose concentration did not significantly affect insulin secretion, indicating that a typical beta-cell response was absent. These observations, along with electron microscopy data showing absence of typical secretory granules, suggest that the insulin-positive cells developed in culture were not beta cells.
Data on insulin gene expression also supported the presence of proinsulin immunoreactivity mainly in cells of neuronal lineage. In our cultures only the Insulin II mRNA was consistently detectable, in agreement with reports showing preferential expression of the Insulin II gene during mouse brain development [41, 47] .
A reporter gene (EGFP) under control of the Insulin I promoter was activated specifically in cells with striking morphological similarities to neurons. In a previous report [17] , activation of similar reporter genes occurred only in one out of 100 000 cells and these cells were not further characterised. In our study up to 1% of the cells turned on the transgene. Surprisingly, activation of the transgenic promoter in two different cell clones was not accompanied by expression of the endogenous Insulin I gene. The explanation for these apparently contradictory results may reside in the fact that the Insulin I gene contains a cis-acting silencer located between −4.0 and −2.0 kb from the transcriptional start site [48] that was not included in the DNA construct used in this study. Since the same promoter region is commonly used for studies on regulation of insulin gene expression, our data caution against interpreting results based only on activation of a similar reporter gene. Of note, the EGFP-positive cells did not express Pdx1. Activation of insulin genes in the absence of this transcription factor was reported for a tumour of neuroectodermal origin [49] and in Pdx1-null mice [50] .
Although the majority of EGFP-positive cells failed to demonstrate the presence of typical neuronal markers, some of them did express the neuron-specific protein GAP-43 [51] . Therefore, EGFP expression could have marked a brief transitional state in the process of neuronal differentiation in which a specific array of expressed transcription factors was able to activate the transgenic Insulin I promoter but not the endogenous one.
When Stage 5 cultures were transplanted into mice in which diabetes had been induced by STZ treatment, hyperglycaemia persisted and no significant effect on the life-span of the animals was observed. The small amount of active hormone produced by the transplanted cells might not have been enough to reverse a severe hyperglycaemia. Alternatively, insulin production could have been further down-regulated upon transplantation, as suggested by the fact that no insulinpositive cells were detected in the grafts. Notably, the engrafted tissue consistently formed teratomas. Although these data are in contrast with previous studies reporting on extension of the animal lifespan [15] or normalisation of the glycaemia [16] , the discrepancy may be due to differences in the procedure used for transplantation and in the severity of the diabetic state induced before transplantation.
In conclusion, we believe that our work, while supporting a previous report [17] , provides answers to crucial issues that had been left unsolved. We demonstrate that the insulin-positive cells that differentiate from nestin-positive cells are not beta cells and, for the first time, that the majority of the cells that are responsible for the insulin expression in culture have neuronal features. Furthermore, we show that such cultures are not suitable for transplantation for the treatment of diabetes. What remains to be investigated is whether (pro-)insulin-expressing neurons can be coaxed to produce and secrete insulin in a glucose-regulated manner. A recent study, showing that insulin-producing neurons are the major suppliers of systemic insulin for maintenance of glucose homeostasis in Drosophila [52] , seems to suggest that such a scenario could be possible if evolution has not erased this ancient neuronal function.
